EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

What determines the optimal pharmacological treatment of atrial fibrillation? Insights from in silico trials in 800 virtual atria

Albert Dasí iD, Michael T B Pope, Rohan S Wijesurendra iD, Tim R Betts, Rafael Sachetto iD, Alfonso Bueno-Orovio, Blanca Rodriguez

The Journal of Physiology · 2023

DOI: 10.1113/jp284730 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Physiology, 2023. Verfasst von Albert Dasí und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Computer Science, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: Atrial Fibrillation, Amiodarone. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation, Wellcome Trust, National Centre for the Replacement, Refinement and Reduction of Animals in Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The best pharmacological treatment for each atrial fibrillation (AF) patient is unclear. We aim to exploit AF simulations in 800 virtual atria to identify key patient characteristics that guide the optimal selection of anti‐arrhythmic drugs. The virtual cohort considered variability in electrophysiology and low voltage areas (LVA) and was developed and validated against experimental and clinical data from ionic currents to ECG. AF sustained in 494 (62%) atria, with large inward rectifier K + current ( I K1 ) and Na + /K + pump ( I NaK ) densities ( I K1 0.11 ± 0.03 vs . 0.07 ± 0.03 S mF –1 ; I NaK 0.68 ± 0.15 vs . 0.38 ± 26 S mF –1 ; sustained vs . un‐sustained AF). In severely remodelled left atrium, with LVA extensions of more than 40% in the posterior wall, higher I K1 (median density 0.12 ± 0.02 S mF –1 ) was required for AF maintenance, and rotors localized in healthy right atrium. For lower LVA extensions, rotors could also anchor to LVA, in atria presenting short refractoriness (median L‐type Ca 2+ current, I CaL , density 0.08 ± 0.03 S mF –1 ). This atrial refractoriness, modulated by I CaL and fast Na + current ( I Na ), determined pharmacological treatment success for both small and large LVA. Vernakalant was effective in atria presenting long refractoriness (median I CaL density 0.13 ± 0.05 S mF –1 ). For short refractoriness, atria with high I Na (median density 8.92 ± 2.59 S mF –1 ) responded more favourably to amiodarone than flecainide, and the opposite was found in atria with low I Na (median density 5.33 ± 1.41 S mF –1 ). In silico drug trials in 800 human atria identify inward currents as critical for optimal stratification of AF patient to pharmacological treatment and, together with the left atrial LVA extension, for accurately phenotyping AF dynamics. image Key points Atrial fibrillation (AF) maintenance is facilitated by small L‐type Ca 2+ current ( I CaL ) and large inward rectifier K + current ( I K1 ) and Na + /K + pump. In severely remodelled left atrium, with low voltage areas (LVA) covering more than 40% of the posterior wall, sustained AF requires higher I K1 and rotors localize in healthy right atrium. For lower LVA extensions, rotors can also anchor to LVA, if the atria present short refractoriness (low I CaL ) Vernakalant is effective in atria presenting long refractoriness (high I CaL ). For short refractoriness, atria with fast Na + current ( I Na ) up‐regulation respond more favourably to amiodarone than flecainide, and the opposite is found in atria with low I Na . The inward currents ( I CaL and I Na ) are critical for optimal stratification of AF patient to pharmacological treatment and, together with the left atrial LVA extension, for accurately phenotyping AF dynamics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationAmiodaroneHumansFlecainideHeart AtriaAction PotentialsAnisolesPyrrolidines

Stichwörter der Autor:innen

atrial fibrillationin silico drug trialsionic currentslow voltage areas

Substanzen

FlecainideAmiodaronevernakalantAnisolesPyrrolidines

Autor:innen und Institutionen

  • Department of Computer Science, University of Oxford, Oxford, UK.
  • Department of Cardiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Department for Human Development and Health, University of Southampton, Southampton, UK.
  • Oxford Centre for Clinical Magnetic Resonance Research, Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Departamento de Ciência da Computação, Universidade Federal de São João del-Rei, São João del-Rei, Brazil.

ORCID-Profile: Albert Dasí, Rohan S Wijesurendra, Rafael Sachetto

Förderung

  • British Heart Foundation
  • Wellcome Trust
  • National Centre for the Replacement, Refinement and Reduction of Animals in Research
  • Fundação de Amparo à Pesquisa do Estado de Minas Gerais

Zitieren

APA

Dasí, A., Pope, M. T. B., Wijesurendra, R. S., Betts, T. R., Sachetto, R., Bueno-Orovio, A., & Rodriguez, B. (2023). What determines the optimal pharmacological treatment of atrial fibrillation? Insights from in silico trials in 800 virtual atria. The Journal of Physiology. https://doi.org/10.1113/jp284730

Vancouver

Dasí A, Pope MTB, Wijesurendra RS, Betts TR, Sachetto R, Bueno-Orovio A, et al. What determines the optimal pharmacological treatment of atrial fibrillation? Insights from in silico trials in 800 virtual atria. The Journal of Physiology. 2023. doi:10.1113/jp284730

BibTeX
@article{Das2023,
  author = {Dasí, Albert and Pope, Michael T B and Wijesurendra, Rohan S and Betts, Tim R and Sachetto, Rafael and Bueno-Orovio, Alfonso and Rodriguez, Blanca},
  title = {What determines the optimal pharmacological treatment of atrial fibrillation? Insights from in silico trials in 800 virtual atria},
  journal = {The Journal of Physiology},
  year = {2023},
  doi = {10.1113/jp284730}
}
Kostenlos starten →